Actively Recruiting
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Led by National Cancer Institute (NCI) · Updated on 2026-04-06
124
Participants Needed
1
Research Sites
560 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18 and older diagnosed with cancer that has the CD70-expressing cancer. Design: Participants will be screened with medical history, physical exam, scans, and other tests. They may by admitted to the hospital. Leukapheresis will be performed. For this, blood is removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. Eligible participants will have an intravenous catheter placed in their upper chest. Over several days, they will get chemotherapy drugs and the anti-CD70 cells. They will recover in the hospital. Participants will take an antibiotic for 6 months after treatment. They will repeat leukapheresis. Participants will visit the clinic every 1-3 months for the first year after treatment, every 6 months for the second year, and then as determined by their physician. Follow-up visits will take 1-2 days. At each visit, participants will have lab tests, imaging studies, and a physical exam. Throughout the study, blood will be taken and participants will have many tests to determine the size and extent of their tumor and the treatment s impact.
CONDITIONS
Official Title
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 72 years
- Cancer expressing CD70 confirmed by tissue testing
- Measurable, unresectable cancer progressing after standard therapy
- 3 or fewer small, stable brain metastases allowed
- ECOG performance status 0 or 1
- Willingness to use birth control during and after treatment
- Negative tests for HIV, hepatitis B and C
- Adequate blood counts and organ function
- Completed prior systemic therapy before enrollment
- Ability to understand and sign informed consent
- Willing to sign durable power of attorney
- Co-enrollment on NCI-SB cell harvest protocol
You will not qualify if you...
- Pregnant or breastfeeding women
- Use of systemic steroids
- Active infections requiring treatment or major uncontrolled illness
- Primary immunodeficiency or autoimmune disease needing immunosuppression
- Opportunistic infections
- Severe allergy to cyclophosphamide, fludarabine, or aldesleukin
- History of coronary artery procedures or symptoms
- Low heart function (LVEF ≤ 45%) if clinically indicated
- Poor lung function (FEV1 ≤ 50%) if clinically indicated
- Participation in other investigational drug studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
Research Team
N
NCI SB Immunotherapy Recruitment Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here